VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

TriAd Cancer Vaccine

Vaccine Information

Vaccine Name: TriAd Cancer Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: None
Antigen: carcinoembryonic antigen (CEA) (NCIT_C91373), brachyury (NCIT_C143034), MUC1 (NCIT_C143035)
Immunization Route: subcutaneous injection
Description: The TriAd Vaccine is a combination of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061) (NCT04247282). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) (NCIT_C91373). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded (NCIT_C143034). ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded (NCIT_C143035). The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment. (NCT04247282)

Host Response

References

NCIT_C143034: Adenoviral Brachyury Vaccine ETBX-051 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034]

NCIT_C143035: Adenoviral MUC1 Vaccine ETBX-061 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035]

NCIT_C91373: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373]

NCT04247282: Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection [https://clinicaltrials.gov/study/NCT04247282]